{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:44:53Z","timestamp":1793781893183,"version":"4.6.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40262-022-01191-6","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T10:04:40Z","timestamp":1672049080000},"page":"101-112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients"],"prefix":"10.1007","volume":"62","clinical-trial-number":[{"clinical-trial-number":"nct02819635","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03653026","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ana Victoria","family":"Ponce-Bobadilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Stodtmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doerthe","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0959-2025","authenticated-orcid":false,"given":"Mohamed-Eslam F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"issue":"3","key":"1191_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cgh.2017.06.016","volume":"16","author":"M Fumery","year":"2018","unstructured":"Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018;16(3):343-56e3. https:\/\/doi.org\/10.1016\/j.cgh.2017.06.016.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"1191_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384\u2013413. https:\/\/doi.org\/10.14309\/ajg.0000000000000152.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1191_CR3","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","volume":"178","author":"PJ Murray","year":"2007","unstructured":"Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623\u20139. https:\/\/doi.org\/10.4049\/jimmunol.178.5.2623.","journal-title":"J Immunol"},{"key":"1191_CR4","unstructured":"AbbVie Inc. RINVOQ\u2122 (upadacitinib extended-release tablets) [US package insert]. North Chicago, IL; 2022."},{"key":"1191_CR5","unstructured":"AbbVie. Rinvoq (upadacitinib) [summary of product characteristics]. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG; 2021."},{"issue":"2","key":"1191_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/cpdd.462","volume":"8","author":"MF Mohamed","year":"2019","unstructured":"Mohamed MF, Zeng J, Marroum PJ, Song IH, Othman AA. Pharmacokinetics of upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis phase 3 trials. Clin Pharmacol Drug Dev. 2019;8(2):208\u201316. https:\/\/doi.org\/10.1002\/cpdd.462.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1191_CR7","unstructured":"Minocha M, Engelhardt B, Stodtmann S, Zhou W, Othman A. Exposure-Response Analyses of Upadacitinib (ABT-494) Efficacy in Subjects with Moderately to Severely Active Ulcerative Colitis-Analyses of a Phase 2 Dose Ranging Induction Study (P0347). In: United European Gastroenterology Week 2018; 21\u201324 October; Vienna, Austria: SAGE; 2018. p. A245."},{"issue":"8","key":"1191_CR8","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ghosh S, Panes J, Schreiber S, D\u2019Haens G, Tanida S, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158(8):2139-49e14. https:\/\/doi.org\/10.1053\/j.gastro.2020.02.030.","journal-title":"Gastroenterology"},{"issue":"4","key":"1191_CR9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/cpt.1671","volume":"107","author":"A Nader","year":"2020","unstructured":"Nader A, Mohamed MF, Winzenborg I, Doelger E, Noertersheuser P, Pangan AL, et al. Exposure-response analyses of upadacitinib efficacy and safety in phase II and III studies to support benefit-risk assessment in rheumatoid arthritis. Clin Pharmacol Ther. 2020;107(4):994\u20131003. https:\/\/doi.org\/10.1002\/cpt.1671.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1191_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s40262-019-00855-0","volume":"59","author":"MF Mohamed","year":"2020","unstructured":"Mohamed MF, Klunder B, Othman AA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin Pharmacokinet. 2020;59(5):531\u201344. https:\/\/doi.org\/10.1007\/s40262-019-00855-0.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1191_CR11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/cpt.1668","volume":"107","author":"MF Mohamed","year":"2020","unstructured":"Mohamed MF, Klunder B, Lacerda AP, Othman AA. Exposure-response analyses for upadacitinib efficacy and safety in the Crohn\u2019s disease CELEST study and bridging to the extended-release formulation. Clin Pharmacol Ther. 2020;107(3):639\u201349. https:\/\/doi.org\/10.1002\/cpt.1668.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1191_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/cts.13146","volume":"15","author":"E Muensterman","year":"2022","unstructured":"Muensterman E, Engelhardt B, Gopalakrishnan S, Anderson JK, Mohamed MF. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials. Clin Transl Sci. 2022;15(1):267\u201378. https:\/\/doi.org\/10.1111\/cts.13146.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"1191_CR13","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/jcph.1782","volume":"61","author":"MF Mohamed","year":"2021","unstructured":"Mohamed MF, Gopalakrishnan S, Teixeira HD, Othman AA. Exposure-response analyses for upadacitinib efficacy in subjects with atopic dermatitis-analyses of phase 2b study to support selection of phase 3 doses. J Clin Pharmacol. 2021;61(5):628\u201335. https:\/\/doi.org\/10.1002\/jcph.1782.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1191_CR14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcph.1550","volume":"60","author":"A Nader","year":"2020","unstructured":"Nader A, Stodtmann S, Friedel A, Mohamed MF, Othman AA. Pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis, Crohn\u2019s disease, ulcerative colitis, or atopic dermatitis: population analyses of phase 1 and 2 clinical trials. J Clin Pharmacol. 2020;60(4):528\u201339. https:\/\/doi.org\/10.1002\/jcph.1550.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1191_CR15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMc1707500","volume":"377","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Panes J. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017;377(5):496\u20137. https:\/\/doi.org\/10.1056\/NEJMc1707500.","journal-title":"N Engl J Med"},{"issue":"10080","key":"1191_CR16","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(16)32126-2.","journal-title":"Lancet"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01191-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01191-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01191-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T11:43:05Z","timestamp":1675424585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01191-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1191"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01191-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,26]]},"assertion":[{"value":"2 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees at AbbVie and may hold AbbVie stock.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest statement"}},{"value":"The studies were conducted in accordance with Good Clinical Practice Guidelines and the ethical principles that have their origin in the Declaration of Helsinki. The protocols were approved by the institutional review board or ethics committee for each site.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Each subject provided written informed consent before any study-related procedures were performed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors provided consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not available.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AbbVie provided financial support for the studies and participated in the study design, study conduct, and analysis and interpretation of data and the writing, review, and approval of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols and Clinical Study Reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. This clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time, and the data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link:\n                      \n                      .","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}}]}}